| 
		UK lawmakers to consider ban on medical supplies from China's Xinjiang
		 Send a link to a friend 
		
		 [April 22, 2022] 
		LONDON (Reuters) - Britain's 
		lawmakers will next week consider proposed changes to legislation that 
		would ban the government from buying medical supplies made in China's 
		Xinjiang region, after pressure from rights groups over Beijing's 
		treatment of the Uyghur people. 
 Rights groups and lawmakers accuse China of widescale abuses against 
		Uyghurs and other minority groups, including the torture, forced labour 
		and detention of one million people in internment camps.
 
 China says the camps are re-education and training facilities and denies 
		any abuse, saying it is fighting religious extremism.
 
 An amendment proposed by Britain's upper house of parliament to the 
		Health and Social Care Bill that would seek to eradicate modern slavery 
		from health service supply chains will be considered by lawmakers in the 
		lower house.
 
		
		 
		[to top of second column] | 
            
			 
            
			A screen shows a picture of Chinese President Xi Jinping at a 
			traffic junction in Hotan, Xinjiang Uyghur Autonomous Region, China, 
			April 30, 2021. REUTERS/Thomas Peter/Files 
            
			 Politico reported that health 
			minister Sajid Javid supported the move. The Department of Health 
			and Social Care had no immediate comment.
 The amendment does not mention Xinjiang specifically but requires 
			the government to ensure the procurement of all goods and services 
			for the health service in England "avoids modern slavery."
 
 Politico said the law change could require private companies 
			obtaining National Health Service (NHS) contracts to meet criteria 
			on modern slavery grounds, potentially creating a blacklist of 
			companies that fail its tests.
 
 (Reporting by James Davey and Kylie MacLellan; Editing by Mark 
			Potter)
 
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |